HER2-positive breast cancer is a specific type of breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). This protein plays a crucial role in the growth and spread of cancer cells. While historically considered more aggressive, significant advancements in HER2-positive breast cancer treatment have dramatically improved outcomes for patients. 

What is HER2-Positive Breast Cancer?

HER2 is a gene that makes HER2 proteins. These proteins are receptors on the outside of all breast cells and are involved in cell growth, division, and repair. In about 15-20% of breast cancers, the HER2 gene is amplified, meaning there are too many copies of the gene, leading to an overexpression of HER2 proteins. This overexpression causes cancer cells to grow and divide more rapidly.

Diagnosis of HER2-positive status typically involves laboratory tests on breast cancer tissue obtained from a biopsy. These tests help oncologists determine the best course of HER2-positive breast cancer treatment, as specific therapies target this protein.

Core Treatment Approaches for HER2-Positive Breast Cancer

The management of HER2-positive breast cancer often involves a multidisciplinary approach, combining various treatment modalities. The specific plan depends on factors like the cancer's stage, patient health, and previous treatments.

Targeted Therapy

Targeted therapies are the cornerstone of HER2-positive breast cancer treatment. These drugs specifically block the HER2 protein, interfering with the cancer cells' ability to grow and divide. They are typically used in combination with chemotherapy or other treatments.

Chemotherapy

Chemotherapy uses powerful drugs to kill rapidly growing cancer cells throughout the body. For HER2-positive breast cancer, chemotherapy is often administered alongside targeted therapy, either before surgery (neoadjuvant) to shrink the tumor, or after surgery (adjuvant) to eliminate any remaining cancer cells.

Surgery

Surgical removal of the tumor is a primary step for most early-stage breast cancers. This can involve a lumpectomy (removing only the tumor and a margin of healthy tissue) or a mastectomy (removing the entire breast). Surgery is often followed by systemic treatments like chemotherapy and targeted therapy.

Radiation Therapy

Radiation therapy uses high-energy rays to destroy cancer cells and is often recommended after lumpectomy to reduce the risk of local recurrence. In some cases, it may also be used after a mastectomy, especially if the tumor was large or if cancer cells were found in the lymph nodes.

Key Targeted Therapies for HER2-Positive Breast Cancer

Advancements in targeted therapies have revolutionized HER2-positive breast cancer treatment. These drugs specifically aim at the HER2 protein, minimizing damage to healthy cells.

Monoclonal Antibodies

• Trastuzumab (Herceptin): This was the first targeted therapy approved for HER2-positive breast cancer and remains a foundational treatment. It binds to the HER2 receptor, blocking signals that tell cancer cells to grow.


• Pertuzumab (Perjeta): Often used in combination with trastuzumab and chemotherapy, pertuzumab targets a different part of the HER2 receptor, providing a more comprehensive blockage.

Antibody-Drug Conjugates (ADCs)

• Trastuzumab emtansine (T-DM1, Kadcyla): An ADC that combines trastuzumab with a chemotherapy drug. It delivers chemotherapy directly to HER2-positive cancer cells, reducing systemic side effects.


• Trastuzumab deruxtecan (Enhertu): Another advanced ADC approved for metastatic HER2-positive breast cancer, showing significant efficacy even in later lines of treatment.

Tyrosine Kinase Inhibitors (TKIs)

• Lapatinib (Tykerb), Neratinib (Nerlynx), Tucatinib (Tukysa): These are oral medications that block HER2 and other related proteins from signaling inside the cell. Tucatinib is particularly notable for its effectiveness against brain metastases in HER2-positive breast cancer.

The Emerging Role of Immunotherapy

Immunotherapy is an area of active research in HER2-positive breast cancer treatment. While not a standard first-line therapy, it is being explored in combination with other treatments, particularly for advanced or refractory cases, to help the body's immune system recognize and fight cancer cells.

Personalized Treatment and Future Outlook

HER2-positive breast cancer treatment is increasingly personalized. Oncologists consider the cancer stage, tumor characteristics, patient's overall health, and potential side effects to devise the most effective plan. Ongoing research continues to identify new therapeutic targets and combinations, offering even more hope for improved outcomes.

Regular communication with your healthcare team is essential to understand your diagnosis and explore the most suitable treatment options for your specific situation. They can provide comprehensive information and guide you through your treatment journey.